Premium
Akcea Therapeutics Inc (AKCA)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product PR Newswire BOSTON and CARLSBAD, Calif., Oct. 30, 2020 BOSTON and CARLSBAD, Calif., Oct...
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Transaction creates a stronger, more efficient company PR Newswire CARLSBAD, Calif., Oct. 12, 2020 CARLSBAD, Calif., Oct. 12...
National Institute for Health and Care Excellence (NICE) issues a positive recommendation for volanesorsen to treat adults with Familial Chylomicronaemia Syndrome (FCS) Akcea Therapeutics UK...
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics - Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash - Transaction...
Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020 Results from Phase 2 study demonstrate patients receiving vupanorsen experienced significant...
Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020 Results in late-breaking presentation show patients with hypertriglyceridemia experienced dose-dependent...
Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020 Late-breaking presentation to focus on efficacy and safety data of vupanorsen in...
Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020 Data presentation will highlight efficacy, safety and tolerability of...
Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany WAYLIVRA is the only treatment option for patients with familial chylomicronemia syndrome, or FCS, in...
Akcea Reports Financial Results and Highlights for Second Quarter 2020 Global Net Product Revenues of $16 Million, an Increase of 66% Year-Over-Year Achieved Pricing and Reimbursement Across Key...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
